Crinetics Pharmaceuticals Inc. announced preliminary and unaudited U.S. net product revenue of over $5 million for the fourth quarter of 2025, primarily driven by the launch of PALSONIFY. PALSONIFY was approved by the U.S. Food and Drug Administration (FDA) on September 25, 2025, for the first-line treatment of adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option. The company reported receiving over 200 enrollment forms in the first three months following FDA approval and indicated a broad prescriber base and ongoing progress toward favorable payer coverage. In addition, Crinetics reported positive topline results from the fourth cohort of its Phase 2 congenital adrenal hyperplasia (CAH) study of atumelnant, a novel oral ACTH receptor antagonist candidate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619566-en) on January 05, 2026, and is solely responsible for the information contained therein.